Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Core Viewpoint - Propanc Biopharma, Inc. has successfully completed an underwritten public offering of 1,000,000 shares at a price of $4.00 per share, raising a total of $4 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The shares commenced trading on the Nasdaq Capital Market under the ticker symbol "PPCB" on August 15, 2025 [1]. - The offering included a 45-day option for the underwriter to purchase an additional 150,000 shares at the public offering price [2]. - The closing of the initial public offering occurred on August 18, 2025 [2]. Group 2: Management and Legal Counsel - D. Boral Capital LLC and Craft Capital Management LLC served as the book running managers for the offering [3]. - Legal counsel for the Company was provided by Brunson Chandler & Jones PLLC, while Sichenzia Ross Ference Carmel LLP acted as counsel to the underwriters [3]. Group 3: Company Overview - Propanc Biopharma, Inc. is focused on developing novel cancer treatments aimed at preventing recurrence and metastasis of solid tumors, particularly targeting pancreatic, ovarian, and colorectal cancers [6]. - The company's approach utilizes pancreatic proenzymes to target and eradicate cancer stem cells [6][7].